With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan
After spending the last 6 months lining up the necessary regulatory OKs, Takeda CEO Christophe Weber has scheduled an upcoming shareholder voter needed to seal its $62 billion deal to buy Shire. And aficionados will note the timeline puts the close right in the middle of the industry’s JPMorgan gathering in early January.
The US and Japan have already offered their blessings to the buyout, leaving Europe ready to announce its decision by November 20. To get their sign off, Takeda agreed to spin out SHP647 along with “certain associated rights” where the EU saw an overlap with its blockbuster Entyvio.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.